Epic Bio to Participate in a Fireside Chat at the Cantor Virtual Muscular Dystrophy Symposium

01 Apr 2024
www.biospace.com
Gene TherapysiRNA
SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman, Ph.D., chief executive officer, will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium at 9:40 a.m. PT, Tuesday, April 2, 2024. Institutional investors should contact their Cantor representatives for additional information. About Epic Bio Epic Bio is a leading epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. Epic plans to begin dosing patients in a clinical trial of its lead program — EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) — in 2024; additional programs seek to address alpha-1 antitrypsin deficiency (A1AD)alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. Visit for more information or follow us on Twitter and LinkedIn. Investor Contact Shawn M. Cox Epic Bio Manager, Investor Relations, and Corporate Communications shawn.cox@epic-bio.com Media Contact Lisa Raffensperger Ten Bridge Communications lisa@tenbridgecommunications.com (617) 903-8783
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.